Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a digital health company focused on multi-chronic condition management through a user-centric digital therapeutics platform, and its news flow reflects developments across technology, clinical evidence, commercial traction and corporate strategy. News items frequently describe how Dario’s platform and suite of solutions deliver personalized, dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Recent announcements have highlighted the launch of DarioIQ™, an artificial intelligence layer integrated into the Dario Health app. This AI capability, initially introduced for a cohort of hypertension members in a direct-to-consumer setting, is described as a clinically aligned, conversational layer that integrates behavioral insights, real-time biometric interpretation and personalized guidance while working alongside Dario’s human coaching framework. The company’s news coverage explains how DarioIQ™ is intended to enhance chronic condition management without replacing human-centered guidance.
DarioHealth’s news also emphasizes peer-reviewed clinical and economic evidence. Publications in JMIR Cardio and the Journal of Medical Internet Research (JMIR) have been featured in press releases, detailing studies of data-driven digital nudges for blood pressure management and analyses of healthcare utilization and medical costs among adults with type 2 diabetes using Dario’s platform compared to matched individuals receiving usual care. These articles are presented as supporting evidence for Dario’s ability to impact outcomes and healthcare burden.
Investors and observers following DRIO news will also see updates on employer and health plan adoption, including the signing of new employer clients and expansion of Dario’s commercial pipeline, as well as financing events such as private placements and strategic reviews initiated by the Board of Directors. Together, these news items provide context on how DarioHealth develops its technology, validates its approach through research and pursues growth with payers, employers and partners.
DarioHealth Corp. (NASDAQ: DRIO) announced a study published in Frontiers in Physiology on Dec. 19, 2022, showcasing its musculoskeletal solution's effectiveness in alleviating back pain. The research analyzed data from 981 users over eight weeks, revealing a 50% average reduction in pain, with 60% of users reporting significant relief after four weeks. The device offers real-time biofeedback to improve posture, resulting in better pain management. Dario's commitment to changing health management behaviors through innovative technology is emphasized, showing potential for chronic pain treatment.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) announced participation in two upcoming investor conferences. The 13th Annual Craig-Hallum Alpha Select Conference will take place on November 17, 2022, in New York City, featuring investor one-on-one meetings. Additionally, the BTIG Digital Health Forum is scheduled for November 21, 2022, as a virtual event, where President Rick Anderson will discuss digital therapeutics at 11:55 a.m. EST. DarioHealth focuses on digital solutions for chronic condition management, delivering personalized care through analytics and coaching.
DarioHealth Corp. (Nasdaq: DRIO) reported third quarter 2022 revenues of $6.6 million, a 17.3% increase from the previous year, driven by strong B2B growth, which now constitutes 63.5% of total revenue. The net loss decreased by 30.3% to $15.6 million. Notably, the company signed 85 B2B contracts valued at over $61 million, with a goal of reaching 100 by year-end. Operating expenses fell by 29.8%, contributing to improved financial health and gross margins of approximately 70% in the B2B segment. A conference call will be held on November 15, 2022.
DarioHealth Corp. (NASDAQ: DRIO) will announce its financial results for Q3 2022 on November 14, 2022, after market close. A conference call and webcast detailing these results will take place on November 15, 2022, at 8:30 am ET. The call will feature executives including CEO Erez Raphael and CFO Zvi Ben-David. Interested participants can join by dialing 1-844-826-3035 (domestic) or 1-412-317-5195 (international) with Conference ID 10173311. The replay will be available until December 15, 2022.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) has secured its first government contract with a Midwestern city to provide digital therapeutic solutions addressing chronic conditions for several thousand city employees. The contract, set to commence in Q1 2023, aims to enhance employee health in diabetes, hypertension, weight management, and behavioral health. This partnership expands Dario's employer footprint, supporting the City’s employee health strategy while aiming for better health outcomes at lower costs.
DarioHealth Corp. (NASDAQ: DRIO) presented new research at the IASP 2022 World Congress on Pain, highlighting the effectiveness of its biofeedback posture trainer in reducing back pain. The study, involving nearly 1,000 participants, found a direct correlation between increased usage of the device and improved posture, leading to reduced pain levels. Dr. Yifat Hershcovitz emphasized the importance of user engagement in achieving positive outcomes. This research furthers Dario's commitment to understanding the mechanisms of clinical improvement in their digital therapeutic solutions.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) reported a Q2 2022 revenue of $6.2 million, marking a 17.5% increase from Q2 2021. The six-month revenue reached $14.2 million, a 60.8% increase. Key developments include a new contract with a national health plan, projected to add nearly 10 million members. The company reported a net loss of $18 million for Q2 2022, with an operating loss of $17.4 million. Operating expenses decreased by 5.2% year-over-year. Dario continues to transition to its B2B2C focus while maintaining a strong pipeline for future growth.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
